An NSAID
Related Products
Active Metabolite(s)
381164-Biphenylacetic Acid
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Fenbufen

Item No. 28851

Technical Information
Formal Name
γ-oxo-[1,1′-biphenyl]-4-butanoic acid
CAS Number
36330-85-5
Synonyms
  • CL 82204
Molecular Formula
C16H14O3
Formula Weight
Purity
≥98%
A crystalline solid
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS (pH 7.2) (1:20): 50µg/mlEthanol: 200 µg/ml
λmax
282 nm
SMILES
O=C(CCC(O)=O)C(C=C1)=CC=C1C2=CC=CC=C2
InChi Code
InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
InChi Key
ZPAKPRAICRBAOD-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    Fenbufen is a non-steroidal anti-inflammatory drug (NSAID) and a prodrug form of 4-biphenylacetic acid.1 Fenbufen (125 μg/ml) inhibits collagen-induced, but not arachidonate-induced, platelet aggregation in vitro.2 In vivo, fenbufen (8-250 mg/kg) suppresses UV-induced erythema in guinea pigs.1 It reduces phenylquinone-induced writhing in mice (ED50 = 7.7 mg/kg) and brewer’s yeast-induced mechano-allodynia in rats (ED50 = 29 mg/kg).2 Fenbufen (28 mg/kg) reduces inflammation in a rat model of adjuvant-induced arthritis. It also reduces yeast-induced fever in rats. Formulations containing fenbufen were previously used in the treatment of osteoarthritis and inflammatory pain.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kerwar, S.S. Pharmacologic properties of fenbufen. Am. J. Med. 75(4B), 62-69 (1983).

    2. Brodgen, R.N., Heel, R.C., Speight, T.M., et alFenbufen: A review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain. Drugs 21(1), 1-22 (1981).